Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells

Cisplatin is widely used as the standard gastric cancer treatment, but the relapse and metastasis are common as intrinsic or acquired drug resistance. CD133 has been widely known to be associated with chemoresistance in various cancer cells. In this study, we focused on investigating the function an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ruiqi, Zhao, Gang, Yang, Yulong, Jiang, Zhaoyan, Cai, Jingli, Hu, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693020/
https://www.ncbi.nlm.nih.gov/pubmed/31405336
http://dx.doi.org/10.1177/1533033819864311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693020/
https://www.ncbi.nlm.nih.gov/pubmed/31405336
http://dx.doi.org/10.1177/1533033819864311

Ejemplares similares